Atyr Pharma Inc(ATYR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 21 at 6:10 PM ET (Korea 10/22 07:10)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.62 | Insider Own | 4.41% | Shs Outstand | 98.1M | Perf Week | -6% |
| Market Cap | 0.02B | Forward P/E | - | EPS next Y | 2.47% | Insider Trans | 2.37% | Shs Float | 93.8M | Perf Month | -51.66% |
| Enterprise Value | -0.03B | PEG | - | EPS next Q | -0.1 | Inst Own | 34.45% | Short Float | 13.75% | Perf Quarter | -65.41% |
| Income | -0.06B | P/S | 88.96 | EPS this Y | 43.12% | Inst Trans | -16.23% | Short Ratio | 3.97 | Perf Half Y | -79.59% |
| Sales | 0.00B | P/B | 0.35 | EPS next 5Y | 22.9% | ROA | -70.97% | Short Interest | 12.89M | Perf YTD | -78% |
| Book/sh | 0.5 | P/C | 0.29 | EPS past 3/5Y | 20.65% 14.76% | ROE | -98.37% | 52W High | -84.48% ($1.11) | Perf Year | -83.27% |
| Cash/sh | 0.59 | P/FCF | - | Sales past 3/5Y | -73.65% -55.14% | ROIC | -103.73% | 52W Low | 4.42% ($0.17) | Perf 3Y | -86.85% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 21.92% | Gross Margin | -732.63% | Volatility(W/M) | 10.15% 10.17% | Perf 5Y | -97.99% |
| Dividend TTM | - | EV/Sales | -154.78 | Sales Y/Y TTM | -19.15% | Oper. Margin | -33609.47% | ATR (14) | 0.02 | Perf 10Y | -99.58% |
| Dividend Ex-Date | - | Quick Ratio | 5.12 | EPS Q/Q | 51.5% | Profit Margin | -32003.68% | RSI (14) | 14.78 | Recom | 2.25 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.12 | Sales Q/Q | - | SMA20 | -30.52% ($0.24) | Beta | 0.96 | Target Price | $2.83 |
| Payout | - | Debt/Eq | 0.23 | Earnings | 2026/8/7 | SMA50 | -55.19% ($0.38) | Rel Volume | 0.37 | Prev Close | $0.17 |
| Employees | 58 | LT Debt/Eq | 0.2 | EPS/Sales Surpr. | 9.39% - | SMA200 | -72.42% ($0.62) | Avg Volume(3M) | 3.24M | Price | $0.17 |
| IPO | 2015/5/7 | Option/Short | Yes/Yes | Trades | 3885 | Volume | 1,212,323 | Change | -0.58% |
🧪 This innovative biotech company develops treatments for immune and fibrotic diseases using proteins derived from human tRNA synthetase. Leveraging its proprietary Neuropilin-2 (NRP2) targeting technology, the company is providing new therapeutic alternatives for patients with pulmonary fibrosis and sarcoidosis.
Over the past 1 year, on the lower side
85% below its 1-year high.
Traded less than usual. That is 37% of its average volume.
ATYR has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +43.1% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $8,896. Peers typically go for $1,161.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -98.0%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 34.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #473 of 595 in the industry
Based on market cap of $17M.
FAQ
What kind of company is ATYR?
ATYR belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ATYR?
The market cap of ATYR is approximately $17M, ranking 5,270 within its sector.
What is the 52-week high and low for ATYR?
ATYR has recorded a 52-week high of $1.11 and a low of $0.17.
